Alpha Cognition Inc. (ACOG)

NCM – Цена в реальном времени. Валюта: USD

5.49

-0.46 (-7.73%)

При закрытии: May 12, 2026, 4:00 PM EDT

07.05.2026

Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Alpha Cognition Inc. (ACOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

28.04.2026

Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

VANCOUVER, B.C. & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its first quarter financial results and business highlights on that date. The financial results and accom.

27.04.2026

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, will participate in three investor conferences in May. Event details are as follows: Market Movers Investor Summit Format: Presentation and 1x1 meetings Date/Time: Tuesday, May 5 at 2.

20.04.2026

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in finance, corporate s.

16.04.2026

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on April 14, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 20,000 shares of common stock to a.

02.04.2026

Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?

Alpha Cognition Inc. (ACOG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

01.04.2026

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,589,099 on March 31, 2026. The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” includes claims covering methods of treating.

Видео

No Data

There is no data to display

Пресс-релизы

20.04.2026

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

16.04.2026

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01.04.2026

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,589,099 on March 31, 2026. The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” includes claims covering methods of treating.

01.04.2026

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425

Dallas, Texas--(Newsfile Corp. - April 1, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition exited FY25 with ZUNVEYL showing increasingly durable traction in long-term care, as 4Q25 net product revenue reached $2.5M and FY25 total revenue reached $10.2M, including $6.8M of ZUNVEYL sales.

Alpha Cognition Inc. (ACOG)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Alpha Cognition Inc. (ACOG)

Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

Видео

No Data

Пресс-релизы

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425

Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

Видео

No Data

Пресс-релизы

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425

Search stocks

Alpha Cognition Inc. (ACOG)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Alpha Cognition Inc. (ACOG)

Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

Видео

No Data

Пресс-релизы

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425

Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

Видео

No Data

Пресс-релизы

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425